Long-term renal consequences of hypertension for normal and diseased kidneys

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 1, 2002, Pages 73-80

  Bidani, Anil K ^a   Griffin, Karen A ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

AUTOREGULATION; BAROTRAUMA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DRUG POTENTIATION; GLOMERULUS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; TIME FACTORS;

EID: 0036143864     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200201000-00011     Document Type: Review

References (90)

1. 1998 Annual Data Report: Incidence and prevalence of ESRD
2. Genetics of renal damage in primary hypertension
3. The link between hypertension and nephrosclerosis
4. Genetic susceptibility to end stage renal disease
5. Hemodynamic theory of progressive renal disease: A 10-year update in brief review
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
7. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
8. The unique vulnerability of diabetic subjects to hypertensive injury
9. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease
10. Progression of diabetic nephropathy
11. Hypertension: Essential and secondary forms
12. Benign nephrosclerosis: Incidence, morphology and prognosis
13. High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension: The case for pressure alone
14. Patterns of blood pressure variability in normotensive and hypertensive rats
15. Modulation of cardiovascular control mechanisms and their interaction
16. Task force III: Target-organ damage, morbidity and mortality
17. Continuous telemetric BP monitoring and glomerular injury in the rat remnant kidney model
18. Method of renal mass reduction is a critical determinant of subsequent hypertension and glomerular injury
19. Genetics of experimental hypertension
20. Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR
21. Chloride-sensitive renal microangiopathy in the stroke-prone spontaneously hypertensive rat
22. Diastolic pressure, systolic pressure, or pulse pressure?
23. Pulse pressure and isolated systolic hypertension: Association with microalbuminuria
24. The effects of diabetes and reduced renal mass on blood pressure power spectra
25. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
26. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials
27. Renal autoregulation: Perspectives from whole kidney and single nephron studies
28. Pressure induced vasoconstriction of renal microvessels in normotensive and hypertensive rats: Studies in the isolated perfused hydronephrotic kidney
29. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats
30. Cerebral blood flow and its pathophysiology in hypertension
31. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney
32. Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron
33. Juxtamedullary microvascular dysfunction during the hyperfiltration stage of diabetes mellitus
34. Altered myogenic responsiveness of the renal microvasculature in experimental hypertension
35. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys
36. Class differences in the effects of calcium channel blockers in the remnant kidney model
37. Comparative effects of T- and L- type calcium channel blockade in the remnant kidney model
38. Preservation of renal autoregulation and not blockade of renal hypertrophy mediates the glomeruloprotection provided by a Iow protein diet in the remnant kidney model
39. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases
40. Anesthetics and renin-angiotensin-aldosterone axis
41. Paracrine regulation of the renal microcirculation
42. Renal blood flow dynamics and arterial pressure lability in the conscious rat
43. Differences between 'steady-state' and 'dynamic' renal autoregulation after renal mass reduction: Implications for susceptibility to hypertensive renal damage
44. Effects of calcium channel blockade on dynamic renal autoregulation: Implications for current interpretations of admittance gain parameters
45. Transforming growth factor and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis?
46. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive gromerulosclerosis
47. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in-vivo
48. Aldosterone in renal disease
49. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
50. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease
51. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat
52. Evolving strategies for renoprotection: Non-diabetic chronic renal disease
53. Mechanisms underlying renoprotection during renin-angiotensin system blockade
54. Add-on angiotensin receptor blockade with maximized ACE inhibition
55. Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model
56. Lack of evidence of BP independent protection by renin-angiotensin system blockade after renal ablation
57. BP-dependence of the protection by renin-angiotensin-aldosterone system blockade in the stroke prone SHR (SHRsp)
58. Genetic susceptibility to hypertension-induced renal damage in the rat: Evidence based on kidney specific genome transfer
59. Increased genetic susceptibility to renal damage in the stroke prone spontaneously hypertensive rat (SHRsp): Evidence based on kidney specific genome transfer
60. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat
61. The effects of angiotensin-converting-enzyme inhibition on diabetic nephropathy
62. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
63. Randomized placebo-controlled trials of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
64. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
65. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
66. Hypertension trials: 1990 to 2000
67. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
68. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
69. The effect of irbesaratan on the development of diabetic nephropathy in patients with type 2 diabetes
70. Comparison of the effects of ramipril on ambulatory and office blood pressures. A HOPE substudy
71. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
72. Early ACE-i intervention in microalbuminuric patients with type 1 diabetes: Effects on albumin excretion, 24 h ambulatory blood pressure, and renal function
73. Pretreatment blood pressure reliably predicts progression of chronic nephropathies
74. Pathophysiology of progressive nephropathies
75. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
76. Evolving strategies for renoprotection: Diabetic nephropathy
77. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood pressure (JNC VI)
78. Preserving renal function in adults with hypertension and diabetes: A consensus approach
79. Effects on blood pressure of reduced dietary sodium and the Dietary Approach to Stop Hypertension (DASH) diet
80. Salt intake and hypertensive renal injury in African-Americans
81. The dominant role of the kidneys in long-term arterial pressure regulation in normal and hypertensive states
82. Renin-angiotensin-aldosterone system and the renal regulation of sodium, potassium and blood pressure homeostasis
83. Renal injury and salt-sensitive hypertension after exposure to catecholamines
84. The use of diuretic therapy in achievement of blood pressure goals in the African-American study of kidney disease and hypertension
85. ACE inhibitor associated elevations in serum creatinine: Is this a cause for concern?
86. Plasma and skeletal muscle electrolytes in patients on long-term diuretic therapy for arterial hypertension and/or congestive heart failure
87. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
88. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high risk patients
89. The effect of spironolactone on morbidity and mortality in patients with severe heart failure